These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31535143)

  • 1. Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
    Adler SP; Lewis N; Conlon A; Christiansen MP; Al-Ibrahim M; Rupp R; Fu TM; Bautista O; Tang H; Wang D; Fisher A; Culp T; Das R; Beck K; Tamms G; Musey L;
    J Infect Dis; 2019 Jul; 220(3):411-419. PubMed ID: 31535143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
    Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Das R; Blázquez-Gamero D; Bernstein DI; Gantt S; Bautista O; Beck K; Conlon A; Rosenbloom DIS; Wang D; Ritter M; Arnold B; Annunziato P; Russell KL;
    Lancet Infect Dis; 2023 Dec; 23(12):1383-1394. PubMed ID: 37660711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
    Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial.
    Fierro C; Brune D; Shaw M; Schwartz H; Knightly C; Lin J; Carfi A; Natenshon A; Kalidindi S; Reuter C; Miller J; Panther L
    J Infect Dis; 2024 Sep; 230(3):e668-e678. PubMed ID: 38478705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.
    Bernstein DI; Reap EA; Katen K; Watson A; Smith K; Norberg P; Olmsted RA; Hoeper A; Morris J; Negri S; Maughan MF; Chulay JD
    Vaccine; 2009 Dec; 28(2):484-93. PubMed ID: 19857446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.
    John S; Yuzhakov O; Woods A; Deterling J; Hassett K; Shaw CA; Ciaramella G
    Vaccine; 2018 Mar; 36(12):1689-1699. PubMed ID: 29456015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
    Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study.
    Murata S; Oshima N; Iwasa T; Fukao Y; Sawata M
    Antibodies (Basel); 2023 Mar; 12(1):. PubMed ID: 36975369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.
    Wloch MK; Smith LR; Boutsaboualoy S; Reyes L; Han C; Kehler J; Smith HD; Selk L; Nakamura R; Brown JM; Marbury T; Wald A; Rolland A; Kaslow D; Evans T; Boeckh M
    J Infect Dis; 2008 Jun; 197(12):1634-42. PubMed ID: 18444883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
    Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
    Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study.
    Langley JM; Gantt S; Halperin SA; Ward B; McNeil S; Ye L; Cai Y; Smith B; Anderson DE; Mitoma FD
    Vaccine; 2024 Jan; 42(3):713-722. PubMed ID: 38142214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
    Bernstein DI; Munoz FM; Callahan ST; Rupp R; Wootton SH; Edwards KM; Turley CB; Stanberry LR; Patel SM; Mcneal MM; Pichon S; Amegashie C; Bellamy AR
    Vaccine; 2016 Jan; 34(3):313-9. PubMed ID: 26657184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus Vaccine.
    Cox KS; Zhang L; Freed DC; Tang A; Zhang S; Zhou Y; Wang IM; Rupp RE; Adler SP; Musey LK; Wang D; Vora KA; Fu TM
    J Infect Dis; 2021 Jun; 223(11):2001-2012. PubMed ID: 33031517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
    Wu K; Hou YJ; Makrinos D; Liu R; Zhu A; Koch M; Yu W-H; Paila YD; Chandramouli S; Panther L; Henry C; DiPiazza A; Carfi A
    J Virol; 2024 Apr; 98(4):e0160323. PubMed ID: 38526054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.
    McVoy MA; Lee R; Saccoccio FM; Hartikka J; Smith LR; Mahajan R; Wang JB; Cui X; Adler SP
    Vaccine; 2015 Dec; 33(51):7328-7336. PubMed ID: 26597035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
    Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
    J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.
    Schneider-Ohrum K; Cayatte C; Liu Y; Wang Z; Irrinki A; Cataniag F; Nguyen N; Lambert S; Liu H; Aslam S; Duke G; McCarthy MP; McCormick L
    J Virol; 2016 Nov; 90(22):10133-10144. PubMed ID: 27581989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dominant Antiviral CD8
    Pardieck IN; van Duikeren S; Veerkamp DMB; Brasem DJ; Redeker A; van Bergen J; Han W; Ossendorp F; Zondag G; Arens R
    Front Immunol; 2022; 13():680559. PubMed ID: 35154089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
    Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
    J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.